Key result
Adjunctive IV magnesium increases rate control odds by ~115% vs placebo in acute fast AF.
Why the study?
The efficacy of intravenous magnesium in managing fast AF has been controversial, with previous meta-analyses yielding conflicting results.
Does intravenous magnesium as an adjunct to standard care improve rate control and rhythm conversion in non-surgical adult patients with acute fast atrial fibrillation?
Meta-Analysis (n=480)
Does intravenous magnesium as an adjunct to standard care improve rate control and rhythm conversion in non-surgical adult patients with acute fast atrial fibrillation?
Odds Ratio: 2.15 (95% CI 0.98–4.73)
p-value: p=0.03
Intravenous magnesium is an effective adjunct to standard care for achieving rate control in non-surgical adults with acute fast atrial fibrillation, though it significantly increases the risk of flushing.
Supports adjunctive IV magnesium for rate control in acute AF; extends meta-analytic evidence for use with standard agents.
Atrial fibrillation (AF) is the most common heart rhythm disorder in the elderly, and it contributes significantly to patient morbidity and mortality. A variety of medications, including amiodarone, beta-blockers, and calcium channel blockers, are commonly used to manage AF. Often, intravenous magnesium (IV Mg) is used as an adjunctive therapy for rate and rhythm control; however, its efficacy in managing fast AF has been controversial, with previous meta-analyses yielding conflicting results. This meta-analysis sought to establish the effectiveness of IV Mg in the treatment of fast AF by incorporating data from a recently concluded randomised controlled trial (RCT) on the same subject. Six RCTs, including 480 patients, comparing IV Mg with placebo in the treatment of fast AF were retrieved after an extensive search of electronic databases. The Mantel-Haenszel (MH) random-effects model was used to estimate the mean effect size across all the included studies. The differences among treatment groups for nominal variables were documented as odds ratios (ORs) with 95% confidence intervals (CIs). The pooled analysis showed that IV Mg given as an adjunct to guidelines-recommended medications had a significant positive impact in achieving rate control (OR: 2.15, 95% CI: 0.98, 4.73, P = 0.03), with no substantial heterogeneity (I² = 60%) as compared to placebo. Similarly, IV Mg was superior to placebo in converting AF rhythm to sinus rhythm (OR: 1.64, 95% CI: 0.90, 2.99, P = 0.18), with moderate heterogeneity (I² = 34%). On safety profile analysis, flushing was more frequently observed in patients who were treated with IV Mg than in those who were given a placebo (OR: 14.12, 95% CI: 3.16, 63.20, P < 0.001), with no statistically significant heterogeneity detected (I² = 0%). The overall OR numerically favoured a higher risk of hypotension with IV Mg compared to placebo; however, the result did not reach statistical significance, and the CI was extremely wide. In conclusion, the meta-analysis establishes that IV Mg administered as an adjunct to the standard guidelines-recommended care is significantly effective for rate control and moderately effective for cardioverting fast AF in adult non-post-operative patients.
No takes yet. Share an insight, caveat, or question.
Mupunga et al. (2026) conducted a meta-analysis in Acute Fast Atrial Fibrillation (n=480). Intravenous Magnesium Sulphate vs. Placebo was evaluated on Rate control (OR 2.15, 95% CI 0.98-4.73, p=0.03). Intravenous magnesium administered as an adjunct to standard care significantly improved rate control (OR 2.15) compared to placebo in non-surgical adult patients with acute fast atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: